All In Biotech

Drug Trial Radar · NCT00163306

Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)

Complete Remission: Evaluation of the Complete Remission Rates in Patients With Symptomatic Non-erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (GERD) Treated With Pantoprazole 40 Milligram o.d. Over 4 or 8 or 12 Weeks

Last checked: Nov 19, 2026Latest source record: May 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

May 2005

Primary completion

Not stated

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 14, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting symptoms related to gastric reflux. Proton pump inhibitors (PPI) such as pantoprazole can relieve symptoms of GERD in a large proportion of patients. When refluxed stomach acidic content touches the lining of the esophagus, it causes a burning sensation in the chest or throat. This sensation is often referred to as heartburn. Some patients have symptoms of GERD without visible destruction of the tissue surface (no visible changes by endoscopic examination). The aim of the study is to evaluate the effect of pantoprazole on the complete remission of GERD. Complete remission is defined as endoscopically confirmed healing and symptom relief after a maximum of 12-week treatment period. Pantoprazole will be administered once daily in the morning. Endoscopy will be performed at the start of the study, and then as required after 4, 8, or 12 weeks. The study will provide further data on safety and tolerability of pantoprazole.

Conditions

  • Gastroesophageal Reflux

Interventions

  • PantoprazoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. complete reflux disease remission rate after 8 weeks of treatment defined as symptom relief assessed by reflux questionnaire (ReQuest Trademark) and endoscopically confirmed healing.

Locations

79 sites in 4 countries. Site status is shown where the registry gives one.

  • Altana Pharma/Nycomed

    Deutschlandsberg, Austria

  • Altana Pharma/Nycomed

    Feldbach, Austria

  • Altana Pharma/Nycomed

    Graz, Austria

  • Altana Pharma/Nycomed

    Graz, Austria

  • Altana Pharma/Nycomed

    Krems A. D. Donau, Austria

  • Altana Pharma/Nycomed

    Lilienfeld, Austria

  • Altana Pharma/Nycomed

    Stockerau, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Vienna, Austria

  • Altana Pharma/Nycomed

    Wiener Neustadt, Austria

  • Altana Pharma/Nycomed

    Amberg, Germany

  • Altana Pharma/Nycomed

    Aschersleben, Germany

  • Altana Pharma/Nycomed

    Bad Bramstedt, Germany

  • Altana Pharma/Nycomed

    Bad Schwalbach, Germany

  • Altana Pharma/Nycomed

    Beckum, Germany

  • Altana Pharma/Nycomed

    Berlin, Germany

  • Altana Pharma/Nycomed

    Berlin, Germany

  • Altana Pharma/Nycomed

    Berlin, Germany

  • Altana Pharma/Nycomed

    Flensburg, Germany

  • Altana Pharma/Nycomed

    Freiburg im Breisgau, Germany

  • Altana Pharma/Nycomed

    Freising, Germany

  • Altana Pharma/Nycomed

    Germersheim, Germany

  • Altana Pharma/Nycomed

    Hamburg, Germany

  • Altana Pharma/Nycomed

    Haßfurt, Germany

  • Altana Pharma/Nycomed

    Herzogenrath, Germany

  • Altana Pharma/Nycomed

    Jülich, Germany

  • Altana Pharma/Nycomed

    Kirchheimbolanden, Germany

  • Altana Pharma/Nycomed

    Landsberg, Germany

  • Altana Pharma/Nycomed

    Langen, Germany

  • Altana Pharma/Nycomed

    Leipzig, Germany

  • Altana Pharma/Nycomed

    Lübeck, Germany

  • Altana Pharma/Nycomed

    Ludwigsburg, Germany

  • Altana Pharma/Nycomed

    Ludwigshafen, Germany

  • Altana Pharma/Nycomed

    Lütjenburg, Germany

  • Altana Pharma/Nycomed

    Magdeburg, Germany

  • Altana Pharma/Nycomed

    Magdeburg, Germany

  • Altana Pharma/Nycomed

    Mönchengladbach, Germany

  • Altana Pharma/Nycomed

    München, Germany

  • Altana Pharma/Nycomed

    München, Germany

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.